Home Your basket
• Cephalic vein access for ...
   Price 10.50 €
• Lysis of the incus long p...
   Price 10.50 €
• Inferior turbinate hypert...
   Price 10.50 €
• Metastatic angiosarcoma t...
   Price 5.50 €
• Choanal atresia: therapeu...
   Price 10.50 €
• Nasal cutaneous cryptococ...
   Price 5.50 €
• Voice prostheses: long-te...
   Price 10.50 €
• Solitary fibrous tumour o...
   Price 8.50 €
• Laryngeal tracheal post-i...
   Price 8.50 €
• Mycobacterial cervical ly...
   Price 10.50 €
• Sphenoid arachnoidocele: ...
   Price 8.50 €
• Ruptured pexis after supr...
   Price 10.50 €
• Phoniatric management of ...
   Price 8.50 €
• Phonatory threshold press...
   Price 10.50 €
• The use of speech therapy...
   Price 10.50 €
• The ultra-low resistance ...
   Price 5.50 €
• Post operative Caldwell-L...
   Price 10.00 €
• Assessment of migraine re...
   Price 8.50 €
• Migrating hypopharyngeal ...
   Price 5.50 €
• Understanding the use of ...
   Price 10.50 €
• Benign paroxysmal positio...
   Price 10.50 €
• Functional anatomy of the...
   Price 14.00 €
• Hygiene and sterilisation...
   Price 10.50 €
• Diagnostic value of vibra...
   Price 8.50 €
• Hearing aid : practical a...
   Price 8.50 €
• Setting up a «Bonebridge»...
   Price 10.50 €
• Sinonasal malignant melan...
   Price 5.50 €
• Contribution of endoscopi...
   Price 8.50 €
• Cochlear implant in elder...
   Price 10.50 €
• Notes on voice and speech...
   Price 8.50 €
• Stingy speakers....
   Price 5.50 €
• Air rifle pellet injury t...
   Price 5.50 €
• Cytokines profile in cyst...
   Price 10.50 €
• Hearing loss and vestibul...
   Price 10.50 €
• Stuttering and Tourette’s...
   Price 5.50 €
• Functional comparison of ...
   Price 14.00 €
• Comparative results of ty...
   Price 10.50 €
• Management of cervical ce...
   Price 10.50 €

Total Order 347.50 €

contents
2019
   N# 1 |
2018
   N# 1 | 2 | 3 | 4 | 5 |
2017
   N# 1 | 2 | 3 | 4 | 5 |
2016
   N# 1 | 2 | 3 | 4 | 5 |
2015
   N# 1 | 2 | 3 | 4 | 5 |
2014
   N# 1 | 2 | 3 | 4 | 5 |
2013
   N# 1 | 2 | 3 | 4 | 5 |
2012
   N# 1 | 2 | 3 | 4 | 5 |
2011
   N# 1 | 2 | 3 | 4 | 5 |
2010
   N# 1 | 2 | 3 | 4 | 5 |
2009
   N# 1 | 2 | 3 | 4 | 5 |
2008
   N# 1 | 2 | 3 | 4 | 5 |
2007
   N# 1 | 2 | 3 | 4 | 5 |
2006
   N# 1 | 2 | 3 | 4 | 5 |
2005
   N# | 1 | 2 | 3 | 4 | 5 |
2004
   N# 1 | 2 | 3 | 4 | 5 |
2003
   N# 1 | 2 | 3 | 4 | 5 |
2002
   N# 1 | 2 | 3 | 4 | 5 |
2001
   N# 1 | 2 | 3 | 4 | 5 |
2000
   N# | 1 | 2 | 3 | 4 | 5 |
1999
   N# 1 | 2 | 3 | 4 | 5 |
1998
   N# 1 | 2 | 3 | 5 |
1997
   N# 1 | 2 | 3 | 4 | 5 |
1996
   N# 4 | 5 |

Click on the number of the review to see the content
Teaching bulletin CME
List of all teaching bulletins CME.
Editor reading committee
Editor reading committee.
To publish...
Instructions for authors
Archives Press and Books
Select of books and press articles.
Mailing list
News information letter.
Subscription prices


If you wish to adjust the size of the displayed characters, click in the high menu on "Your account" and choose the desired size.



  Contents > Previous page > Article detail print Order
o Issue N# 3 - 2017 o

OTOLOGY

Observational study to assess the effect of Audistim® on the quality of life of patients presenting with chronic tinnitus


Authors : Frachet B, Portmann D, Allaert FA. (Paris, Bordeaux, Dijon)

Ref. : Rev Laryngol Otol Rhinol. 2017;138,3:79-85.

Article published in english
Downloadable PDF document english



Summary : Objectives: To evaluate the improvement of symptoms, quali­ty of life, psychological stress and sleep quality of patients suffering from chronic tinnitus after a 3 months intake of Audistim®. Methods: Observational study of Audistim® by ENT doctors in patients consulting them for chronic tinnitus. Evaluation criterion: THI quality of life score, PSQI sleep score, MSP-9 Stress score. Patients were examined at baseline and at 3 months. Results: 314 patients aged 54.1 ± 13.0 years and suffering from tinnitus since 5.8 ± 7.3 years were included in the study. At the end of the 3 months, patients’ quality of life chan­­ged from 44.6 ± 23.4 to 26.7 ± 18.7 corresponding to an impro­vement of 40.1% (< 0.0001), subjects’ stress from 38.5 ± 13.3 to 30.1 ± 10.8 to 3 months corresponding to an improve­ment of 21.8% (<0.0001) and sleep quality of 8.4 ± 4.5 to 5.4 ± 3.2 corresponding to an improvement of 35.7%. Quality of life improvement was significantly correlated with stress impro­vement (r: 0.77 (p< 0.0001) and sleep (r: 0.70 (p< 0.0001). Tinnitus were improved in 70.0% of patients according to doc­tors, and in 69% of them according to the patients themselves. 2.8% of patients experienced adverse events, essentially diges­tive, none of which was judged by doctors as imputable to the intake of Audistim®. Conclusion: The original composition of Audistim® combining several active ingredients used to control tinnitus gives rise to clear improvements in the quality of life, stress and sleep of the patients experiencing tinnitus and provides them satisfaction without the risk of adverse events.


Price : 14.00 €      order
|


Subscribe online - Pay by credit card!


© Copyright 1999-2024 - Revue de Laryngologie   Réalisation - Hébergement ELIDEE